- The prime time for management of hepatocellular carcinoma in Hong Kong
-
Chan LL, Chan SL
- KMID: 2541413
- Clin Mol Hepatol.
- 2023 Apr;29(2):345-348.
- doi: 10.3350/cmh.2023.0094
-
- CITED
-
- Close
- SHARE
-
- Close
- The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
-
Chan LL, Chan SL
- KMID: 2546377
- Clin Mol Hepatol.
- 2023 Oct;29(4):909-923.
- doi: 10.3350/cmh.2023.0114
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
-
Lee MMP, Chan LL, Chan SL
- KMID: 2546408
- J Liver Cancer.
- 2023 Sep;23(2):262-271.
- doi: 10.17998/jlc.2023.07.17
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor... -
- CITED
-
- Close
- SHARE
-
- Close
